Targeted Therapies and Imaging Biomarkers: Revolutionizing ITP and Coronary Inflammation Management

Abstract

Precision medicine is increasingly shaping clinical practice in both hematology and cardiology by promoting therapies and diagnostics rooted in disease mechanisms. In immune thrombocytopenia (ITP), rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, represents a targeted strategy that addresses key drivers of the disease. By reducing autoantibody production and limiting immune-mediated platelet destruction, it has demonstrated sustained platelet responses while potentially avoiding the broader immunosuppressive effects seen with conventional treatments. Its mechanism also raises the possibility of application in other autoimmune conditions. In cardiology, attention has turned toward pericoronary adipose tissue (PCAT) attenuation measured on coronary computed tomography angiography as a marker of coronary inflammation. Unlike traditional imaging that focuses primarily on luminal narrowing, PCAT assessment offers insight into vascular inflammatory activity and may enhance cardiovascular risk prediction. Although these developments are promising, important challenges remain, including long-term tolerability, cost considerations, and technical standardization. Together, these advances reflect both the opportunities and the complexities involved in translating precision medicine from theory into everyday clinical care.